| 000 | 01814 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250515073323.0 | ||
| 264 | 0 | _c20081030 | |
| 008 | 200810s 0 0 eng d | ||
| 022 | _a1618-7598 | ||
| 024 | 7 |
_a10.1007/s10198-007-0058-1 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKarnon, Jonathan | |
| 245 | 0 | 0 |
_aCost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective. _h[electronic resource] |
| 260 |
_bThe European journal of health economics : HEPAC : health economics in prevention and care _cMay 2008 |
||
| 300 |
_a171-83 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnastrozole |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Hormonal _xadministration & dosage |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aLetrozole |
| 650 | 0 | 4 | _aMarkov Chains |
| 650 | 0 | 4 | _aNeoplasm Recurrence, Local |
| 650 | 0 | 4 |
_aNeoplasms, Hormone-Dependent _xdrug therapy |
| 650 | 0 | 4 |
_aNitriles _xadministration & dosage |
| 650 | 0 | 4 | _aPostmenopause |
| 650 | 0 | 4 | _aQuality of Life |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 |
_aTamoxifen _xadministration & dosage |
| 650 | 0 | 4 |
_aTriazoles _xadministration & dosage |
| 650 | 0 | 4 |
_aUnited Kingdom _xepidemiology |
| 700 | 1 | _aDelea, Thomas | |
| 700 | 1 | _aBarghout, Vicki | |
| 773 | 0 |
_tThe European journal of health economics : HEPAC : health economics in prevention and care _gvol. 9 _gno. 2 _gp. 171-83 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s10198-007-0058-1 _zAvailable from publisher's website |
| 999 |
_c17138679 _d17138679 |
||